FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.
The FDA greenlighted a highly anticipated pancreatic cancer treatment that has altered the prospects for patients facing the deadly disease.
The agency on Wednesday approved …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
FDA approves ‘game-changing’ pancreatic cancer drug
'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma
FDA approves breakthrough drug to treat advanced pancreatic cancer
FDA approves new drug Rasonque to treat advanced pancreatic cancer
FDA approves new pancreatic cancer drug expected to usher in new era of treatment
